Dengue vaccine study using two vaccines together to strengthen and broaden immunity
Official title: A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV
Funded at Emory University · NIH-11418927 · Data updated 2026-11-12
A Phase 2b trial tests whether giving TAK-003 followed by Butantan-DV boosts broad, durable antibodies against dengue in adults who have been vaccinated before.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 19, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $666,595 |
| NIH project number | 5U01AI186860-02 |
| Project ID | NIH-11418927 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults who have received prior dengue vaccination and are eligible for participation in this phase 2b trial.
✕Less likely to help
Individuals who cannot receive vaccines due to safety or medical contraindications may not benefit.
What this research studies
This trial looks at how a prime-boost approach with two dengue vaccines affects the immune system’s antibodies against all four dengue types. Researchers will measure memory B cell responses and antibody levels over time to see if the combination provides broader protection. It is designed to be conducted in adults at risk for dengue and will follow participants closely for safety and immune responses. The goal is to learn whether this strategy can reduce future dengue illness and improve vaccine effectiveness.
Why it matters
Potential benefit: If successful, the approach could lead to stronger, longer-lasting protection against dengue for people in endemic areas and travelers.
How similar studies have gone: Prior dengue vaccine trials have shown variable efficacy; this study explores a novel prime-boost strategy to improve breadth and durability of protection.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Collins, Matthew — Emory University
- Study coordinator: Collins, Matthew
Related research
Other NIH-funded projects on the same topics.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Movement-Enhanced Walking Training to Improve Balance After Stroke
A specialized treadmill training using a cable-driven device, called Movement Amplification Environment (MAE), helps people with chronic stroke improve walking balance by enhancing their own movement awareness.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.